Table 3.

Six selected compounds with the highest minimum docking scores, annotated with their marketing approval status, indications, most frequently observed side effects, minimum docking score, and average docking score. Docking scores provide a rough estimation of binding energy (ΔG, kcal/mol) [27,28]. Lower scores indicate higher binding affinity. Docking scores may vary depending on the system, however generally scores less than −7.5 indicate high affinity binding.

Name	Status	Indication1	Side Effects2	Min Score	Avg Score
Otamixaban	Experimental	Thrombosis	Catheter site hematoma	−10.81	−7.29
			Gastrointestinal hemorrhage
			Vascular pseudoaneurysm
Argatroban	Marketed	Thrombosis	Increased INR	−8.45	−6.29
		Heparin induced thrombocytopenia	Prolonged aPTT
			Hemorrhage
Nafamostat	Marketed	Disseminative blood vessel coagulation	Platelet count decreased	−8.14	−5.08
			Abnormal hepatic function
Letaxaban	Experimental	Thrombosis	Angina Pectoris	−7.60	−6.26
			Epistaxis
		Venous thromboembolism	Hematuria
Darexaban	Experimental	Thrombosis	Bleeding events	−6.67	−5.83
		Venous thromboembolism
Edoxaban	Marketed	Thromboembolism	Gastrointestinal hemorrhage	−6.62	−5.43
			Epistaxis
		Deep vein thrombosis
			Rash

¹Indications were compiled from FDA drug labels and clinical trial records.

²Side effects were compiled from the FDA adverse event reporting system (FAERS) and clinical trial records.